This article reports that HHS Secretary Robert F. Kennedy, Jr. announced the FDA will remove the black box warning from hormone replacement therapy for menopausal and post-menopausal women, explains why the move reverses decades of caution rooted in a flawed study, cites specific benefits and risks discussed by officials, and notes who attended the announcement.
Secretary of Health and Human Services Robert F. Kennedy, Jr. announced a significant policy shift Monday: the Food and Drug Administration will remove the black box warning from hormone replacement therapy products used to treat low hormone levels in menopausal and post-menopausal women. The announcement signals a clear change in federal tone toward women’s health and medical decision-making. This action directly addresses treatment hesitancy that followed earlier warnings and aims to reframe clinical guidance for physicians and patients.
Black box warnings are the strictest labels the FDA uses when a drug poses a serious hazard, and they have long shaped prescribing patterns for hormone replacement therapy. HRT first received such a warning in the early 2000s after the Women’s Health Initiative study reported concerns about breast cancer risk. That finding caused HRT use among menopausal women to fall sharply and left many women struggling with severe symptoms like hot flashes and night sweats.
Officials now say that the original study had important flaws that distorted the risks. The average age of women in that study was 63, which is substantially older than the typical age when women begin menopause. Participants were also using a hormone formulation that is not commonly prescribed today, making the old data a poor fit for current practice and modern formulations.
In reviewing the evidence anew, the FDA concluded that women who begin hormone replacement therapy within ten years of menopause and typically before age 60 gain benefits beyond symptom relief. The agency highlighted evidence that HRT is linked to a reduced risk of all-cause mortality and fractures, and cited studies showing a 50% reduction in heart attack risk, a 64% reduction in cognitive decline, and a 35% lower risk of Alzheimer’s. Those figures are central to the argument that benefits can outweigh the risks for many patients when therapy is started at the appropriate time.
“That ends today,” said Kennedy said of untreated menopause symptoms at a Monday press conference he conducted alongside FDA Commissioner Marty Makary. “The era of ignoring women’s health is over,” Secretary Kennedy continued. “We’re challenging outdated thinking and recommitting to evidence-based medicine.” Those words framed the announcement as corrective and urgent, pushing back on what officials described as decades of caution that sometimes amounted to neglect.
The FDA’s reassessment sought to separate early dogma from modern evidence, especially when timing and formulation matter. When therapy begins closer to the onset of menopause, outcomes appear substantially different than they did in long-criticized older trials. Regulators argue that clinicians should have access to updated labeling that reflects these nuances so women can make informed choices with their doctors.
FDA Commissioner Makary emphasized the scale of the impact when he said, “Tens of millions of women have been denied the life-changing and long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk.” That statement underscores the administration’s message that policy, not just medicine, influences patient access and that correcting policy can restore care options.
The announcement attracted high-level attention; Second Lady Usha Vance and Secretary of Labor Lori Chavez-DeRemer were present at the event. Their attendance underscored the political importance attached to women’s health issues in this moment. The presence of senior figures helped frame the decision as part of a broader push to put medical evidence and patient needs first.
Critics will no doubt question the shift and push for ongoing scrutiny, and clinicians will need clear guidance on which patients are appropriate candidates for therapy. The FDA and HHS are positioning this move as a recalibration rather than a blanket endorsement for all women at all ages. The central claim from officials is that when used in the right window of time, HRT can offer meaningful protection against serious outcomes while also treating disruptive menopausal symptoms.
Add comment